Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monovalent Oral Polio Vaccine Sabin strain
- Development stage
- Phase 4
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Monovalent Oral Polio Vaccine (mOPV) Sabin strain is a live, attenuated poliovirus vaccine containing only one serotype of the Sabin strain. It is administered orally and stimulates both mucosal and humoral immunity. This vaccine is primarily used in targeted outbreak response rather than routine immunization.
- Brand names
- Bio-Polio
- Other names
- Monovalent OPVSabin monovalent vaccine
02
Targets
PTBP1 (Polypyrimidine tract-binding protein 1)EIF4G1 (Eukaryotic translation initiation factor 4 gamma 1)
Beyond the preview
Go deeper on Monovalent Oral Polio Vaccine Sabin strain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Monovalent Oral Polio Vaccine Sabin strain.